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Abstract
Background: In intensive care unit (ICU) patients, many 
laboratory measurements can be deranged when com-
pared with the standard reference interval (RI). The 
assumption that larger derangements are associated with 
worse outcome may not always be correct. The ICU-Labome 
study systematically evaluated the univariate association 
of routine laboratory measurements with outcome.
Methods: We studied the 35  most frequent blood-based 
measurements in adults admitted ≥6 h to our ICU between 
1992 and 2013. Measurements were from the first 14 ICU 
days and before ICU admission. Various metrics, includ-
ing variability, were related with hospital survival. ICU- 
based RIs were derived from measurements obtained at 
ICU discharge in patients who were not readmitted to the 
ICU and survived for >1 year.
Results: In 49,464 patients (cardiothoracic surgery 43%), we 
assessed >20 · 106 measurements. ICU readmissions, in-hos-
pital and 1-year mortality were 13%, 14% and 19%, respec-
tively. On ICU admission, lactate had the strongest relation 
with hospital mortality. Variability was independently 
related with hospital mortality in 30 of 35 measurements, 
and 16 of 35 measurements displayed a U-shaped outcome-
relation. Medians of 14 of 35 ICU-based ranges were outside 
the standard RI. Remarkably, γ-glutamyltransferase (GGT) 
had a paradoxical relation with hospital mortality in the 
second ICU week because more abnormal GGT-levels were 
observed in hospital survivors.
Conclusions: ICU-based RIs for may be more useful than 
standard RIs in identifying ICU patients at risk. The asso-
ciation of variability with outcome for most of the meas-
urements suggests this is a consequence and not a cause 
of a worse ICU outcome. Late elevation of GGT may confer 
protection to ICU patients.
Keywords: γ-glutamyltransferase; critical care; lactate; 
outcome; reference interval; variability.
Introduction
Critically ill patients often have laboratory measurements 
that are abnormal when compared with standard refer-
ence intervals (RIs). The use of standard RIs derived from 
healthy persons to assess disease severity or identify com-
plications may sometimes be inappropriate in patients in 
the intensive care unit (ICU). In order to identify specific 
pathophysiological mechanisms or to develop multivari-
ate predictive models for critically ill patients, many ICU 
studies have evaluated the relation between selected 
measurements and outcome [1–5]. Depending on which 
measurements are selected or which clinical phase is con-
sidered of interest, measurements were from patients who 
may be outside the standard RI.
It has been proposed to define RIs for specific patient 
groups such as hospitalized patients [6]. Moreover, the 
implicit assumption that a more deranged measurement 
will be associated with a worse clinical situation may not 
always be correct.
The goals of the ICU-Labome study were to com-
prehensively evaluate the univariate relation of regular 
laboratory measurements with outcome and to identify 
“ICU-based” RIs, derived from ICU patients who were 
discharged and had no major complications as reflected 
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by no ICU readmission and 1-year survival. Parameter-
specific a priori assumptions or multivariate models such 
as APACHE [2, 3] were not the scope of this study. We also 
checked for potential U-shaped relations with outcome 
and whether measurement variability was associated with 
outcome, as observed for glucose and potassium [7–9].
Materials and methods
Supplementary material
Given the scope of this study, some methods and the majority of the 
(intermediate) results of analyses are reported in an extensive Sup-
plementary Material File (SMF.pdf), so we could consistently report 
the various aspects of all the 35 measurements.
Patients and outcome
From 1992 through 2013, all laboratory measurements from all 
patients admitted to our tertiary 44-bed ICU in a University Hospital 
were evaluated (Figure 1). Patients ≥15 years were included and data 
were directly anonymized before further analysis. The type of ICU 
admission was recorded, and when patients were admitted multiple 
times to the ICU, the first ICU admission of the last hospital admis-
sion was used. Patients who stayed <6 h at the ICU were excluded.
In-hospital mortality was the main outcome measure. ICU mor-
tality, ICU readmission, lengths of stay and 1-year survival were also 
recorded. The hospital information system is periodically updated with 
national survival status information for patients treated in the ICU.
Selection, correction and primary reduction 
of  measurements
We selected the 35  most frequently assessed laboratory measure-
ments in the blood during the first 14  days of ICU stay, or directly 
preceding ICU admission. The numbers 35 and 14  were arbitrarily 
chosen to cover the vast majority of measurements. Derived values 
such as base excess were excluded. The standard RIs used were those 
used by our central diagnostic laboratory in December 2013 (Table 1). 
We excluded only obviously impossible values, typically resulting 
from data entry or storage mistakes. This concerned negative, zero or 
extreme values for assays that could not possibly report such values. 
Some standard RIs were modified over the 22-year study period. We 
50,942 Unique patients 
49,464 Patients
23,482,000 Measurements in blood
Laboratory dataPatients
ICU-Labome data selection and reduction
22-year period (1992–2013)
Excluded: age <15 years
2917 admissions 
Excluded: previous or
later ICU admission*
6746 admissions
Excluded: ICU stay <6 h
1296 patients
60,605 ICU admissions
Age ≥15 years
57,688 admissions
Hospital survival
42,780 patients (86%)
No ICU readmission
and 1-year survival
35,750 (72%) patients
25,467,000
Laboratory measurements 
20,421,000 Measurements for
top 35 parameters
Linear correction of 10 parameters in
older time periods
4,738,000
Means  at baseline, ICU day 1 to 14
and 12 h before ICU discharge 
Excluded: 1,985,000
measurements in
urine or other fluids
ROC analyses
(Figure 2, SMF §4)
Variability and
U-shape analyses
(Table 2, SMF §14)
“ICU-based”
reference intervals
(Table 2)
Time curves  X
outcome
(Figure 3, SMF §5 )
Heatmap
(Figure 4, SMF
§11, §13)
Soccer-plots
(Figure 3,
SMF §7, §8)
Bivariate
correlations
(SMF §3)
Figure 1: Data flow.
Flowchart depicting selection of patients, selection of the top 35 laboratory parameters and subsequent data reduction and analysis. 
*In case of multiple ICU stays, only the first ICU stay of the last hospital admission was used.
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verified for measurements whether abrupt time-dependent long-term 
changes had occurred, and if required we performed a linear correc-
tion to adjust such measurements (SMF §9).
ICU days 1 through 14 were determined in 24-h blocks count-
ing from the date and time of ICU admission. When patients had 
multiple measurements within the same ICU day, the mean was 
calculated before further analysis, except for the analysis of vari-
ability. For measurements directly preceding ICU admission, the 
mean over the 120  h before ICU admission was considered the 
baseline value.
Table 1: Laboratory measurements evaluated.
Abbreviation   Measurement   Unit   sRI1  Type of relation 
with mortality2
  Variability 
and mortality4
  ‘ICU-based’ RI: 
median (IQR)5
  Median of ICU-based 
RI relative to sRI1
ALAT   Alanine aminotransferase   U/L   <45  Monotonic   +++    30 (20–48)  in sRI5
Alb   Albumin   g/L   35–50  U-shaped   +   28 (24–32)  <sRI5
Amy   Amylase   U/L   <107  Monotonic   +   67 (38–115)  in sRI
AP   Alkaline phosphatase   U/L   <115  Monotonic   +   55 (43–75)  in sRI
aPCO2   Arterial pCO2   kPa   4.6–6.0  U-shaped   ++    5.0 (4.7–5.5)  in sRI
apH   Arterial pH     7.35–7.45  U-shaped   ++    7.40 (7.37–7.43)  in sRI
aPO2   Arterial PO2   kPa   9.5–13.5  U-shaped   ++    12.4 (10.6–15.0)  in sRI
APTT   Activated partial 
thromboplastin time
  s   23–33  Monotonic   +   27 (25–31)  in sRI
ASAT   Aspartate aminotransferase  U/L   <35  Monotonic   +   40 (28–62)  >sRI5
aSatO2   Arterial oxygen saturation     0.96–0.99  Monotonic   +   0.98 (0.96–0.99)  in sRI
Bic   Bicarbonate   mmol/L   21–25  Monotonic   +   23 (21–25)  in sRI
Ca   Calcium (total)   mmol/L   2.20–2.60  U-shaped   ++    1.96 (1.84–2.08)  <sRI
CK-MB   Creatine MB kinase   U/L   <5  Monotonic   +   14 (8–24)  >sRI
CKT   Total creatine kinase   U/L   <170  U-shaped3   −   215 (121–415)  >sRI
Cl   Chloride   mmol/L   97–107  U-shaped   ++ +    107 (104–110)  >sRI
Creat   Creatinine   μmol/L   50–110  Monotonic   ++    68 (57–83)  in sRI
CRP   C-reactive protein   mg/L   <5  Monotonic   −   57 (23–107)  >sRI
DBI   Direct bilirubin   μmol/L   <5  Monotonic   +   4 (2–7)  in sRI
GGT   γ-Glutamyltransferase   U/L   <55  Monotonic   −   36 (18–86)  in sRI
Glu   Glucose   mmol/L   4.0–6.0  U-shaped   ++    7.4 (6.3–8.9)  >sRI
Hb   Hemoglobin   mmol/L   7.7–10.6  U-shaped   ++ +    6.4 (5.8–7.2)  <sRI
Ht   Hematocrit   mmol/L   0.36–0.52  U-shaped   ++    0.30 (0.28–0.3)  <sRI
K   Potassium   mmol/L   3.5–5.0  U-shaped   ++    4.3 (4.0–4.6)  in sRI
Lac   Lactate   mmol/L   0.5–1.5  Monotonic   −   1.0 (0.8–1.4)  in sRI
LDH   Lactate dehydrogenase   U/L   <248  Monotonic   ++    297 (213–408)  >sRI
Leuko   Leukocyte count   109/L   4–10  U-shaped3   ++    12.2 (9.7–15.3)  >sRI
Mg   Magnesium   mmol/L   0.70–1.00  Monotonic   −   0.95 (0.82–1.11)  in sRI
Na   Sodium   mmol/L   135–145  U-shaped   ++    137 (135–139)  in sRI
P   Phosphate   mmol/L   0.70–1.50  U-shaped3   ++    1.02 (0.85–1.20)  in sRI
PLC   Platelet count   109/L   150–350  U-shaped   ++    180 (138–239)  in sRI
PT   Prothrombin time   s   9.0–12.0  Monotonic   +   11.6 (10.8–12.7)  in sRI
TBI   Total bilirubin   μmol/L   <17  Monotonic   +   10 (7–16)  in sRI
TP   Total protein   g/L   60–80  U-shaped   +   53 (47–59)  <sRI
Trop   Troponin   ng/L   <14  Monotonic   +   51 (15–124)  >sRI
Urea   Urea   mmol/L   2.2–7.5  Monotonic   +   6.4 (4.9–8.7)  in sRI
Key characteristics and results of 35 laboratory parameters evaluated in the ICU-Labome study. 1sRI: standard reference interval as pro-
vided by the central laboratory. 2All parameters obtained showed a univariate relation with in-hospital mortality, and for 13 parameters 
this relation was U-shaped when a quadratic function was used. 3For three additional parameters (CKT, leuko and P), a U-shape was 
only found with a more complex polynomial function (SMF §14). 4The relation of standard deviation (SD) as a measure of variability with 
in-hospital mortality was classified as detailed in the methods section from ‘−’ through ‘+++’. Thus, an independent association of vari-
ability with in-hospital mortality was present for the majority of parameters. Furthermore, in 16 of the 35 parameters, SD had a stronger 
relation with outcome than the mean (i.e. ‘ + + ’and ‘ + + + ’). 5Medians with interquartile ranges (IQR) obtained at discharge in patients 
who achieved good outcome (i.e. no readmission to the ICU and survival >1 year) were be used as ‘ICU-based’ RIs. 5‘in sRI’, “<sRI” and 
“>sRI”, respectively, denote that the median ICU-based value provided in the previous column is within, below or above the standard 
reference interval (sRI). For 14 of the 35 measurements, the median of the “ICU-based IQR” was found to be outside the standard refer-
ence interval.
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Bivariate correlations
We performed bivariate linear regression analysis for the 
35 ·(35 − 1)/2 measurement pairs to identify strongly related or obvi-
ously redundant measurements. Data from all patients and ICU days 
were pooled for this analysis.
Area under the receiver operating characteristics curve 
(AUROC)
To assess the univariate monotonic relation with outcome of the 
35  measurements on ICU day 1,  we determined the AUROC with 
 in-hospital mortality as the dependent variable. Likewise, AUROCs 
were calculated for all measurements for ICU day 2, the change 
from ICU days 1 to 2, and for the 12-h window before ICU discharge. 
Note that measurements with a known U-shaped relation (see 
below) with outcome will do relatively poorly in AUROC analysis 
because this analysis assumes a monotonic relation of a test value 
with outcome.
Variability (SD) and outcome
The relation of variability for the 35  measurements obtained up 
to ICU day 14  with in-hospital mortality was assessed. Similar to 
how variability has been determined for glucose [8] or potassium 
[9], variability of each measurement for each patient was defined 
as the standard deviation (SD) of all measurements, including 
multiple measurements on the same day, obtained during the ICU 
stay. Whether the SD was relevantly associated with outcome was 
assessed by performing logistic regression analysis with in-hospital 
mortality as dependent and the measurement’s mean and SD as 
independent factors.
SD’s association with outcome was classified as follows:
 – ‘−’ No association;
 – ‘+’ Both SD and mean were associated with outcome, but mean 
had a stronger association;
 – ‘++’ Both SD and mean were associated with outcome, but SD 
had a stronger association;
 – ‘+++’ Only SD was associated with outcome.
U-shaped relation with outcome
For some measurements (e.g. sodium), both low and high levels are 
associated poor outcome. To assess the presence of such a U-shaped 
relation with outcome, logistic regression analysis was used with 
the individual mean measurement (x) and the squared mean meas-
urement (x2) on ICU day 1 as independent parameters and in-hos-
pital mortality as dependent parameter. A U-shaped relation was 
considered present when both coefficients of the quadratic function 
were significant and the parabola had a minimum (i.e. lowest point 
of the U-curve) that was situated within the 10%–90% range of all 
individual means. A more complex polynomial fractional function 
with the terms x−2, x−1, x0.5, x and x2 was also explored in a similar 
manner.
Time course of medians and soccer plots
We compared the time course of the medians ± interquartile range 
(IQR) of the 35 laboratory measurements between hospital survivors 
and hospital non-survivors.
‘Soccer’ plots [10] were constructed to provide additional graph-
ical information on the distribution of values in relation with the 
standard RI, as a function of ICU day for in-hospital survivors and 
non-survivors. Values within the standard RI are green, whereas yel-
low, orange and red reflect values both below and above the standard 
RI, according to detailed criteria (SMF §6).
The observed distribution of laboratory measurements may have 
structurally changed over the years, either because changes in the 
ICU (e.g. glucose control) or because of changes in the laboratory (e.g. 
a modified assay for albumin). For visual recognition of structural 
changes in the distribution of the 35 reported measurements, soccer 
plots were also made for the 1992–2002 and 2003–2013 periods.
‘ICU-based’ RIs
We used ICU patients who were not readmitted to the ICU and sur-
vived for ≥1 year to generate ‘ICU-based’ reference ranges [6]. The 
clinical period that was used to obtain these laboratory measure-
ments was the last 12 h of the ICU admission before ICU discharge. 
To obtain conservative estimates, IQRs (i.e. P25%–P75%) were deter-
mined, and not the P2.5% and P97.5% as is usually done for standard 
RIs derived from a population of normal individuals.
Heat map
One would expect that when laboratory measurements are deranged, 
i.e. below or above the standard RI, that in the sickest patients such 
measurements would be furthest from the standard RI. To verify this, 
we examined when median levels in patients who died during the 
same hospital stay were more deranged than in patients who sur-
vived. A heat map was constructed to summarize in a single figure 
for all 35 median measurements at all time points whether they were 
more deranged (orange or red), similarly deranged (gray) or less 
deranged (green or dark green) in non-survivors than survivors.
Statistics
Distributions were compared with the χ2-test and medians with the 
Mann-Whitney U-test. Logistic regression analyses were used only 
for one of the 35 measurements at the time. As construction of mul-
tivariable predictive models was not a goal of this study, no models 
using multiple lab measurements were used. In order to assess the 
contribution the variability of a parameter x (i.e. SD) to outcome, 
the mean and SD of x were entered as factors into logistic regres-
sion analysis. Similarly to assess a U-shaped relation, x and x2 were 
entered (SMF §14). To identify more complex U-shaped relations, we 
also performed the same analyses with the terms x−2, x−1, x0.5, x and 
x2 (fractional polynomials [11]) with conditional backward elimi-
nation of terms with a p ≤ 0.10 for entry and p ≥ 0.05 for removal of 
Brought to you by | Ghent University Library
Authenticated
Download Date | 12/14/18 11:38 PM
1144      Alkozai et al.: ICU-Labome study
terms. Plots of all 35 quadratic (SMF §14.1a to §14.35a) and fractional 
polynomial fits (SMF §14.1b to §14.35b) were generated to enhance 
interpretation. SPSS version 23 from IBM was used for all analyses 
and Microsoft Excel and Powerpoint 2010  were used for graphical 
 representations.
Ethics approval and consent to participate
This study was approved by our institutional review board (IRB), 
the “Medisch ethische toetsingscommisie of the University Medical 
Center Groningen” (METC 2014.264). Because only anonymized data 
that had been obtained during routine care were analyzed and no 
additional sampling or interventions were performed for this ret-
rospective study, the IRB considered informed patient consent not 
 necessary.
Results
The overall major data reduction and synthesis stages 
with the corresponding numbers of patients and measure-
ments are shown in Figure 1.
Patients and outcome
Over the study period, there were 60,605 ICU admis-
sions (Figure 1). Excluded were 18% (<15 years: 5%; ICU 
 re-admission: 11%; ICU stay <6  h: 2%). The mean ± SD 
age of the selected population was 60 ± 16  years, 37% 
were females and 18% were admitted from the emergency 
department. The largest admission category was cardio-
thoracic surgery (Table 2).
Mean ICU and hospital length of stay were 4.3 ± 9.6 
and 18 ± 21  days, and the frequency distributions of 
the ICU length of stay did not markedly change from 
1992–2002 to 2003–2013 (SMF §2). Thirteen percent 
of the patients were readmitted to the ICU during the 
same hospital stay. ICU, in-hospital and 1-year mortal-
ity were 11%, 14% and 19%, respectively. Non-survivors 
had longer ICU stays than survivors (SMF §2.2). Of all 
studied ICU patients, 72% were not readmitted and were 
still alive after 1 year.
Selection, correction and primary reduction 
of measurements
Of 23 · 106 blood measurements recorded, 20 · 106 (87%) 
were included (Figure 1). The frequency distribution of the 
number of mean measurements per ICU day is provided 
in SMF §1.1. For 10  measurements, linear adjustments 
were made (SMF §9.2) due to evident structural changes in 
reported laboratory values over the years. In several cases 
(e.g. albumin), the running means of the median labora-
tory values still reflected considerable gradual changes 
even after these corrections (SMF §10).
Bivariate correlations
Many of the 595 measurement pairs examined showed a 
positive R (SMF §3). The highest Rs were +0.96 and +0.97 
for the hemoglobin, hematocrit and direct bilirubin, total 
bilirubin pairs, respectively. Fewer negative correlations 
were observed and these were not as marked as positive 
correlations. The most negative R was −0.50 for the apH, 
lactate pair.
AUROC
Thirty-two out of 35 laboratory measurements had an 
AUROC >0.50. Lactate on ICU day 1  showed the strong-
est predictive power for in-hospital mortality (AUROC of 
0.731; 95% CI: 0.722–0.740; Figure 2) as well as lactate on 
Table 2: Patient characteristics.
No. of patients 49,464
Age, years (SD) 60 (16)
Sex, male 63%
Admission from emergency department 18%
Type of admission
 Cardiothoracic surgery 42.5%
 Abdominal, vascular and miscellaneous surgery 14.5%
 Neurosurgery 11.2%
 Medical 5.8%
 Trauma 3.8%
 Transplantation 1.8%
 Miscellaneous 20.4%
Mean (SD) ICU staya, days 4.3 (9.6)
Median (IQR) ICU staya, days 1.0 (0.8–3.1)
Mean (SD) hospital stay, days 18 (21)
Median (IQR) hospital stay, days 11.6 (7.2–21.0)
ICU readmission 13%
ICU mortality 11%
In-hospital mortality 14%
1-year mortality 19%
Patients in reference groupb 72%
ICU, intensive care unit; IQR, interquartile range; SD, standard 
deviation. aICU stay includes ICU stay for readmissions. bPatients in 
this group had no ICU readmission and where alive after 1 year. This 
group was used to calculate ICU based reference intervals.
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ICU day 2. AUROC data for ICU day 1 and 2, the change 
from ICU days 1 to 2, and at <12 h before ICU discharge are 
provided in SMF §4.
Variability (SD) and outcome
For 30 of the 35 measurements, SD had an independent 
relation with in-hospital mortality (Table 1). Moreover, in 
16 of these measurements, the SD had a stronger relation 
with outcome than the mean (alanine aminotransferase 
[ALAT], arterial partial CO2 pressure [aPCO2], arterial pH 
[apH], aPO2, calcium, chloride, creatinine, glucose, hemo-
globin, hematocrit, potassium, lactate dehydrogenase 
[LDH], leukocyte count, sodium, phosphate and platelet 
count; Table 1). 
U-shaped relation with outcome
At ICU day 1, all 35 parameters evaluated showed a univar-
iate relation with in-hospital mortality, and in 16 of them 
(Table 1), this relation was U-shaped.
Time course of medians and soccer plots
Time courses of the medians of all 35 measurements for 
hospital survivors and non-survivors and the associated 
p-values are provided in SMF §5.1–§5.35 and §11, respec-
tively. Two of the most remarkable time courses, lactate 
and γ-glutamyltransferase (GGT), are shown in Figure  3. 
Lactate was considerably higher at all time points in 
non-survivors (p < 10−21 to p < 10−300) and GGT was initially 
higher (p < 3 · 10−156) but subsequently lower in non-survi-
vors (p < 5 · 10−7).
The soccer plots (SMF §7) demonstrate that for some 
parameters, most measurements were outside the stand-
ard RI (e.g. albumin, SMF §7.2), whereas for other para-
meters (e.g. potassium, SMF §7.23), most were inside the 
standard RI but extreme values predominantly occurred 
in non-survivors. Comparison of soccer plots between 
1992–2002 and 2003–2013 shows that many changes over 
the first 14 ICU days have remained similar over the past 
decades (SMF §8). However, some exceptions are evident. 
Albumin, apCO2, chloride, hemoglobin, hematocrit and 
sodium [10] became more deranged during ICU stay in the 
2003–2013 period, whereas glucose became less deranged. 
These effects might be explained by well-known changes 
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Figure 2: AUROC analysis on ICU day 1.
Univariate relation of laboratory parameters on ICU day 1 with in-hospital mortality as assessed by area under the receiver operating curve 
(AUROC). We assessed the univariate prognostic relevance of 35 studied laboratory variables on ICU day 1. All parameters had an AUC 
higher than 0.5, except for the total creatine kinase (CKT), hemoglobin (Hb), and potassium (K). Lactate (Lac), urea, and creatinine were the 
strongest predictors of in-hospital mortality at ICU day 1. Blue color reflects a positive relation with mortality; red color reflects an inverse 
relation with mortality. Note that the AUROC will do poorly for variables with a U-shaped outcome relation. AUROC are displayed with 95% 
confidence intervals.
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in therapeutic strategies concerning which laboratory 
deviations are deemed acceptable.
A clear feature of some parameters is their complex 
time dependency over the first 14 ICU days. Most extreme 
was the quadriphasic behavior of the leukocyte count 
(SMF §5.26, §7.26, §8.26). Although the leukocyte count 
was consistently higher in non-survivors, it can be appre-
ciated that these time fluctuations diminish leukocytosis’ 
association with prognosis [12].
‘ICU-based’ RIs
When the median IQR laboratory values observed within 
12  h of ICU discharge in patients who were not readmit-
ted to the ICU and survived 1 year were considered as ICU-
based IQRs, for 14 of the 35 laboratory measurements the 
median value of these ICU-based IQRs was outside the 
standard RI (albumin, aspartate aminotransferase [ASAT], 
calcium, CK-MB, total CK, chloride, CRP, glucose, hemo-
globin, hematocrit, LDH, leukocyte count, total protein 
and troponin; Table 1). Thus, many “abnormal” laboratory 
measurements before the discharge from the ICU were not 
“abnormal” from a prognostic point of view.
Heat map
The heat map (Figure 4) indicates that many parameters 
are more deranged (i.e. red) at most or all time points 
(albumin, apH, APTT, bicarbonate, calcium, creatinine, 
lactate, PT and urea) in non-survivors with underlying 
p-values as low as <10−300 (SMF §11). Several parameters 
did not show differences at most time points, and few 
showed a ‘paradoxical’ difference (light and dark green) 
with a more deranged value in survivors. Between 
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Figure 3: Time courses of lactate and γ-glutamyltransferase (GGT) and outcome.
Changes in lactate and GGT during the first 14 ICU days graphically represented in two different manners. The two upper panels show medians 
with interquartile ranges for survivors (green) and non-survivors (red). Lactate showed the strongest discrimination between survivors and non-
survivors for all 35 measurements that were evaluated. At all time points non-survivors had higher lactate levels. GGT was initially significantly 
lower for in-hospital survivors, but it increased to levels that are higher than and more out of range than those of non-survivors from ICU day 6 
onwards. Gray bars denote standard reference intervals; **p < 0.0005; *p < 0.01. The lower panels are soccer plots with green areas denoting 
measurements in the standard reference ranges, and yellow, orange and red denoting progressively more deranged values (see detailed descrip-
tion SMF §6). The soccer plot also indicates after ICU day 5 that survivors had more deranged GGTs than non-survivors.
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ICU days 5 and 14, only GGT showed highly significantly 
more deranged values in survivors. This paradoxical rela-
tion was also present when only patients who stayed 
≥14 days in the ICU were analyzed 9 (SMF §12.1). Likewise, 
it was also observed in subgroup analyses for the cardio-
thoracic surgery (43%) and non-cardiothoracic surgery 
(57%) groups (SMF §13), as well for the miscellaneous 
surgery, trauma, and medical categories (SMF §12.2).
Discussion
In this comprehensive analysis of the blood-based 
measurements, we found that for 14 of the 35 most used 
parameters, the ICU-based RI that we determined was 
outside the standard RI. Furthermore, our results under-
score that early lactate has the strongest predictive value 
for in-hospital mortality of 35 laboratory measurements 
that were assessed. Also, we found that for most of the 
35  measurements, variability had an independent rela-
tion with outcome. Close examination of the time courses 
in survivors and non-survivors over the first 14 ICU days 
uncovered a unique characteristic of GGT compared to 
other laboratory measurements. In the second week of 
ICU admission, the GGT levels were more deranged in sur-
vivors compared to non-survivors.
This analysis of regularly performed laboratory 
measurements had no a priori assumptions about 
specific mechanisms. We only hypothesized that the 
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Figure 4: Heat map.
For the 35 parameters studied, red and orange in this heat map indicate that derangements (i.e. distance from official reference interval) 
for in-hospital non-survivors were larger than derangements for survivors (red: p < 0.0005; orange: p < 0.01). Gray indicates no significant 
difference between non-survivors and survivors. Green indicates a ‘paradoxically’ larger derangement for survivors than non-survivors (light 
green: p < 0.0005; dark green: p < 0.01), as observed for a few early measurements (e.g. aPCO2) that show an early paradoxical relation with 
outcome. After prolonged ICU stay, only GGT shows a consistently more deranged level in survivors. In SMF §13.1 and §13.2 heat maps of 
cardiothoracic surgery patients and non-cardiothoracic surgery patients are shown.
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standard RIs may not be a reliable tool in assessing 
critically ill patients because many patients still have 
derangements upon the discharge from the ICU. In 
fact, it has previously been shown that adjusted RIs 
for the ICU population decrease false-positive results 
and increase true-negative results [13]. Many laboratory 
derangements do not endanger the ICU patient, do not 
necessitate further intervention and should not preclude 
discharge from the ICU. Other derangements – although 
not life- threatening  – might require attention in short-
term clinical management. Obviously, when an observed 
value falls within the IQR as found in discharged ICU 
patients with a relatively good outcome, this does not 
automatically imply that this value is associated with 
minimal risk. In order to assess the mortality risk asso-
ciated with a specific laboratory parameter value, even 
more advanced analyses are required [14, 15].
Concerning lactate, it has become evident that stress 
and not hypoxia is the most important driver of hyperlac-
tatemia, which may explain its unique association with 
outcome [16–18]. Recently, the Sepsis-3 consensus incor-
porated lactate into the clinical definition of septic shock 
[19]. However, in common scoring systems used to predict 
mortality in ICU patients [2–5], many laboratory variables 
of lesser prognostic power are incorporated, but lactate is 
not yet included. We believe our results further support 
the routine use and inclusion of lactate into future scoring 
systems. The ICU-based RI for lactate closely corresponds 
with the standard RI (Table 1); thus, optimal lactate levels 
in ICU patients approach reference levels in healthy 
individuals.
The bivariate correlations showed that the (hemo-
globin, hematocrit) and the (total bilirubin, direct bili-
rubin) pairs were strongly correlated, confirming that 
hematocrit in most cases is redundant on top of hemo-
globin [20, 21]. Likewise, the apparent unconditional 
ordering of both total bilirubin and direct bilirubin meas-
urements will not provide much additional information 
compared to total bilirubin alone, at least for our overall 
patient group.
With regard to measurement variability, it is remark-
able that this metric was related with outcome for 30 out 
of 35 measurements. Although there has been a consider-
able focus on glucose variability as a therapeutic goal, it 
is should be noted that the variability of – among others – 
several blood gas parameters, sodium and potassium had 
a stronger relation with outcome than the mean of these 
parameters (Table 1). In our judgment, this suggests that 
higher variabilities in patients who do worse are a funda-
mental reflection of the clinical instability of such patients 
[7–9, 22]. Thus, unless a specific explanatory mechanism 
indicates otherwise, higher laboratory parameter instabil-
ity should be considered a consequence and not a cause of 
a worse clinical situation.
Regarding the U-shaped relation of 16 measurements 
with outcome (Table 1), there were few unexpected find-
ings. All these measurements, with the possible excep-
tion of albumin, are known to manifest both pathological 
‘hypo’ and ‘hyper’ states.
In our view, the most surprising finding of our study 
was the paradoxical relation of GGT with outcome. GGT 
is a key enzyme in modulating redox-sensitive (extra)
cellular defenses against toxins [23–26]. It is constitu-
tively expressed in several organs and it breaks down 
 extracellular glutathione (GSH), which generates cysteine 
for intracellular de novo synthesis of GSH. Higher serum 
GGT plausibly reflects increased cellular GGT activity 
and serum GGT increases with chronic exposure to toxic 
metabolites. Apart from its known association with the use 
of several drugs and ethanol [23], chronically elevated GGT 
in apparently healthy persons has emerged as strong risk 
factor for cardiovascular disease [27]. Likewise, in patients 
with liver disease, elevated GGT is considered a marker of 
cholestasis together with indicators such as bilirubin and 
alkaline phosphatase. We observed earlier that secondarily 
elevated GGT was associated with increased survival rates 
after liver transplantation, liver resection and after surgi-
cal repair of a ruptured abdominal aortic aneurysm [28–
30]. The current observation in a large cohort of critically 
ill patients as well as in patients with prolonged ICU stay 
(SMF §12.1) or in subgroups without known primary liver 
disease (e.g. cardiothoracic or trauma patients; SMF §12.2) 
supports the notion that transiently elevated GGT is cru-
cially involved in protective mechanisms leading to better 
outcome of ICU. In patients with acetaminophen intoxica-
tion, restoration of GSH levels with acetylcysteine treat-
ment is critical [31, 32] as acetylcysteine provides cysteine 
for intracellular de novo synthesis of GSH. The benefit of 
acetylcysteine for related conditions is still unproven [33]. 
The possibility that interventions which increase GGT 
levels, such as GGT-inducing drugs [23], might also confer 
protection has also not been tested.
We believe that this paradoxical GGT relation could 
be confirmed in many existing ICU databases but has 
probably been overlooked because most studies focus on 
the first few ICU days. At the very least, caregivers should 
realize that the development of an elevated GGT in the 
second ICU week is not worrisome and should not auto-
matically lead to investigations into its cause.
With regard to the other measurements that were 
green on the heat maps, these differences all occurred 
early during ICU stay with only small absolute differences 
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(e.g. hemoglobin, chloride or total protein; SMF §5, §11). 
Late “paradoxical” effects were seen for only few para-
meters, such as total creatine kinase activity (CKT) at dis-
charge (Figure 4). It has been demonstrated earlier that 
lower enzyme activity levels can reflect a worse outcome 
[34]. However, comparison of heat maps of cardiothoracic 
surgery patients with other patients (SMF §13.1 and §13.2) 
indicates that this is a confounding effect from the large 
number of elective cardiothoracic surgery patients that 
have elevated postoperative CKT activity but have a lower 
mortality compared to other patients. It is should also be 
remarked that the heat maps have many gray zones that 
reflect phases when abnormalities may be present but 
that do not discriminate for outcome.
A large body of ICU literature addresses the association 
of deviating laboratory measurements and outcome [1–5, 14, 
15]. Our observations fully corroborate this because patients 
who did not survive the hospital admission had far more 
deranged laboratory measurements (Figure 4). However, 
our results may also have some practical consequences 
as they clearly show that the association of laboratory 
derangements with in-hospital mortality may sometimes 
be time dependent. Also, ICU care providers should realize 
that an abnormally high GGT may not necessarily be a cause 
for alarm or specific diagnostic procedures. In addition, our 
data underscore that many laboratory derangements in 
critically ill patients should not be considered “abnormal” 
from the prognostic point of view since derangements of 14 
out of 35 laboratory measurements at ICU discharge were 
not associated with poor outcome (i.e. readmission to the 
ICU or diseased within 1 year).
Our study has a several limitations, some resulting from 
its retrospective design. We did not use commonly used ICU 
severity scores such as APACHE [2, 5] because these were 
not fully available. Many scoring systems such as APACHE 
use the most extreme daily value, not the daily mean as 
we did. Although using extremes often will improve a 
model’s predictive value, this involves additional arbitrary 
choices. To avoid this, we opted for the daily mean for all 
35 measurements. We only performed univariate analysis of 
laboratory measurements with outcome as it was not our 
aim create multivariable predictive models. Multivariable 
models can easily suffer from incorrect fits, including over-
fitting [35]. The way we defined the patient reference group 
(no ICU readmission and 1-year survival) may be considered 
arbitrary. However, we wanted to use a straightforward and 
reproducible criterion to identify the patients with a rela-
tively good outcome [6]. Including 1-year survival served 
to exclude patients who did poorly post ICU discharge but 
were not readmitted to the ICU for various reasons. Cover-
ing more than two decades, many potential confounding 
changes in measurement or therapy may have occurred, 
although data were at least partially adjusted for time 
effects (SMF §8, §10). The 1992–2002 vs. 2003–2013 soccer 
plots underscore that apart from the exceptions noted 
earlier, the behavior of most parameters has not essentially 
changed. During the ICU stay differences in the frequency 
of ordering measurements between certain patient groups 
may also have led to some bias, although no large differ-
ences in sampling between survivors and non-survivors 
were observed (SMF §1.2, §2.2). We do believe the extensive 
study period increased the robustness and external validity 
of many of our observations.
Despite our goal to analyze without a priori hypoth-
eses, a number of choices had to be made, such as the 
limit of 35 measurements and the selected time windows. 
We chose to depict time courses of survivors and non-sur-
vivors over the 14 ICU days for all ICU patients, and not 
only those who had an ICU stay of ≥14  days. A majority 
of the patients were surgical patients with cardiothoracic 
surgery as a large subgroup (43%). However, the GGT-
effect was also observed in other patient groups (SMF 
§12) and a heat maps of cardiac and non-cardiac surgery 
patients showed many similarities (SMF §13.1 and §13.2). 
Likewise, the time-dependent behavior of GGT was com-
parable between all patients and patients with an ICU stay 
≥14 days (SMF §5.19 and §12.1).
We believe that our results represent clinically rel-
evant information for the assessment of critically ill 
patients. Thus, we are confident that the observations can 
also be reproduced in other ICU cohorts. ICUs possessing 
large cohorts stored in integrated patient database man-
agement systems should also be able to explore relations 
between treatment and subsequent laboratory changes, 
such as an elevated GGT.
Conclusions
The use of ICU-based RI’s instead of standard RI’s may 
decrease the level of uncertainty in clinical decision 
making. The widespread association of parameter vari-
ability with outcome makes it doubtful whether reducing 
variability of specific parameters is a useful therapeutic 
goal. Moreover, late elevation in GGT apparently confers 
a good outcome.
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